Investment

For research investors, 2006 was the year that the European train finally started to leave the station. The new year will tell whether it’s going anywhere worth visiting.

The number of venture-backed exits grew in value and number in 2005 – and the upward trends are expected to continue into 2007.

Europe needs more "angel" investors to finance its start-ups. A Prague conference highlights why it isn't getting them.

European exchanges are opening back up for riskier ventures, and experts expect the trend to continue. But trade-sales should still dominate, says Mary Lisbeth D'Amico.

Shares in Oxford BioMedica, an Oxford University spin-out, fell 8.3 percent on news that the company was seeking up to £30 million to fund the Phase III trial of its a TroVax cancer immunotherapy product.

US biotechnology firm DOR BioPharma plans to build a bigger force in gastro-intestinal medicines by buying Copenhagen-based Gastrotech Pharma, a spin-out of Gothenburg University in Sweden.

Celoxica, an Oxford University spin-out that makes chip design software, blamed “depressive market” conditions for the company raising less capital than it initially expected in its initial public offering

British drug-delivery company Phoqus blamed "unfavourable market" conditions for meeting only its minimum target of £10 million in its initial public offering.